Karol Skłodowski (Poland)

Medical University of Bialystok Department of Medical Microbiology and Nanobiomedical Engineering

Author Of 1 Presentation

ANTIMICROBIAL ACTIVITY OF GOLD NANOPARTICLES COATED WITH CERAGENIN CSA-13 AGAINST HIGHLY-VIRULENT AND ANTIBIOTIC-RESISTANT ACINETOBACTER BAUMANNII

Date
Thu, 12.05.2022
Session Time
10:00 - 11:30
Session Type
Oral Presentations Session
Room
MC 2 HALL
Lecture Time
10:42 - 10:52

Abstract

Backgrounds:

The overuse of antibiotics has led to the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria, and as a result very often we lack effective therapeutic options for infections caused by these strains. This study was designed to determine in vitro antimicrobial activities of nanosystems containing gold nanoparticles and ceragenin (cationic steroidal antimicrobial) CSA-13 against Acinetobacter baumannii strain.

Methods

The clinical strain (A. baumannii resistant to carbapenems, aminoglycosides and fluoroquinolones) was subjected to treatment with rod- (AuR), peanut- (AuP), and star-shaped (AuS) gold nanoparticles (Au NPs) coated with CSA-13. Minimal inhibitory and bactericidal concentrations, colony counting assays and a resazurin-based proliferation assays were used to determine bactericidal efficacy. Additionally, adherence and internalization of the pathogens to lung-derived cells (A549) as well as biocompatibility of the tested compounds were evaluated.

Results:

AuR NPs@CSA-13, AuP NPs@CSA-13 and AuS NPs@CSA-13 shown high antimicrobial activity, regardless of the identified mechanism of drug resistance. Both internalization and adherence of the tested strain were restricted and dose-dependent in a cell culture model. Importantly, tested compounds at bactericidal concentrations were characterized by satisfactory biocompatibility.

Conclusions/Learning Points:

The applied gold nanosystems exhibit strong antimicrobial activity against a MDR A. baumannii strain, which makes them promising agents to develop as new therapeutic options to eradicate multidrug-resistant pathogens.

The project was funded by the National Science Centre granted under contract number UMO-2018/31/B/NZ6/02476

Hide

Presenter Of 1 Presentation

ANTIMICROBIAL ACTIVITY OF GOLD NANOPARTICLES COATED WITH CERAGENIN CSA-13 AGAINST HIGHLY-VIRULENT AND ANTIBIOTIC-RESISTANT ACINETOBACTER BAUMANNII

Date
Thu, 12.05.2022
Session Time
10:00 - 11:30
Session Type
Oral Presentations Session
Room
MC 2 HALL
Lecture Time
10:42 - 10:52

Abstract

Backgrounds:

The overuse of antibiotics has led to the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria, and as a result very often we lack effective therapeutic options for infections caused by these strains. This study was designed to determine in vitro antimicrobial activities of nanosystems containing gold nanoparticles and ceragenin (cationic steroidal antimicrobial) CSA-13 against Acinetobacter baumannii strain.

Methods

The clinical strain (A. baumannii resistant to carbapenems, aminoglycosides and fluoroquinolones) was subjected to treatment with rod- (AuR), peanut- (AuP), and star-shaped (AuS) gold nanoparticles (Au NPs) coated with CSA-13. Minimal inhibitory and bactericidal concentrations, colony counting assays and a resazurin-based proliferation assays were used to determine bactericidal efficacy. Additionally, adherence and internalization of the pathogens to lung-derived cells (A549) as well as biocompatibility of the tested compounds were evaluated.

Results:

AuR NPs@CSA-13, AuP NPs@CSA-13 and AuS NPs@CSA-13 shown high antimicrobial activity, regardless of the identified mechanism of drug resistance. Both internalization and adherence of the tested strain were restricted and dose-dependent in a cell culture model. Importantly, tested compounds at bactericidal concentrations were characterized by satisfactory biocompatibility.

Conclusions/Learning Points:

The applied gold nanosystems exhibit strong antimicrobial activity against a MDR A. baumannii strain, which makes them promising agents to develop as new therapeutic options to eradicate multidrug-resistant pathogens.

The project was funded by the National Science Centre granted under contract number UMO-2018/31/B/NZ6/02476

Hide